Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

NCT03452228 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hypertriglyceridemia (sHTG)

Interventions

DRUG: evinacumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals